These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Myasthenia gravis after allogeneic bone marrow transplantation. Shimoda K, Gondo H, Harada M, Sano T, Nakamura M, Otsuka T, Okamura S, Niho Y. Bone Marrow Transplant; 1994 Jul; 14(1):155-6. PubMed ID: 7951105 [Abstract] [Full Text] [Related]
3. Myasthenia gravis after allogeneic bone marrow transplantation. A case report and a review of the literature. Zaja F, Barillari G, Russo D, Silvestri F, Fanin R, Baccarani M. Acta Neurol Scand; 1997 Oct; 96(4):256-9. PubMed ID: 9325479 [Abstract] [Full Text] [Related]
4. Myasthenia gravis without chronic GVHD after allogeneic bone marrow transplantation. Baron F, Sadzot B, Wang F, Beguin Y. Bone Marrow Transplant; 1998 Jul; 22(2):197-200. PubMed ID: 9707030 [Abstract] [Full Text] [Related]
5. Myasthenia gravis after allogeneic bone marrow transplantation: report of a new case and pathogenetic considerations. Grau JM, Casademont J, Monforte R, Marín P, Grañena A, Rozman C, Urbano-Márquez A. Bone Marrow Transplant; 1990 Jun; 5(6):435-7. PubMed ID: 2369684 [Abstract] [Full Text] [Related]
9. Myasthenia gravis and polymyositis as manifestations of chronic graft-versus-host-disease. Tse S, Saunders EF, Silverman E, Vajsar J, Becker L, Meaney B. Bone Marrow Transplant; 1999 Feb; 23(4):397-9. PubMed ID: 10100585 [Abstract] [Full Text] [Related]
10. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation. Russell CA. Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093 [Abstract] [Full Text] [Related]
13. Acute disseminated encephalomyelitis (ADEM) after allogeneic bone marrow transplantation for acute myeloid leukemia. Tomonari A, Tojo A, Adachi D, Iseki T, Ooi J, Shirafuji N, Tani K, Asano S. Ann Hematol; 2003 Jan; 82(1):37-40. PubMed ID: 12574963 [Abstract] [Full Text] [Related]
19. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies. Naparstek E, Nagler A, Or R, Kapelushnik J, Slavin S. Clin Transpl; 1996 Jan; ():281-90. PubMed ID: 9286578 [Abstract] [Full Text] [Related]